Form 4: John Patience Reports Stock Transactions in Biodesix Inc.

John Patience, Chairman and Director of Biodesix Inc., reports the vesting and acquisition of 46,686 common stock shares through restricted stock units on March 31, 2025.

Summary

• John Patience, Chairman and Director of Biodesix Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 31, 2025, 46,686 restricted stock units (RSUs) vested, each representing one share of Biodesix's common stock.
• Patience acquired these 46,686 shares of common stock upon the vesting of the RSUs.
• Following the transaction, Patience directly owns 384,612 shares.
• Patience also indirectly owns 2,153,298 shares through Patience Enterprises LP, 4,829,611 shares through John Patience Living Trust dated 7/23/1993, and 52,988 shares through a spouse.
• The RSUs vested in full on March 31, 2025, and have no expiration date.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing is a standard disclosure of stock transactions. The vesting of RSUs is generally a positive sign, but it's a routine event.

Positives

• The vesting of RSUs indicates that performance milestones were likely met, which is a positive signal.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, which can be informative for investors.

Stakeholder Impact

• The transaction could have a minor impact on shareholders by slightly increasing the number of outstanding shares.

Key Dates

Keywords

Form 4, Beneficial Ownership, Restricted Stock Units, BDSX, Biodesix Inc., John Patience, Stock Transaction